CN115327137A - 一种人免疫球蛋白g4亚型化学发光免疫检测试剂盒 - Google Patents
一种人免疫球蛋白g4亚型化学发光免疫检测试剂盒 Download PDFInfo
- Publication number
- CN115327137A CN115327137A CN202211237465.XA CN202211237465A CN115327137A CN 115327137 A CN115327137 A CN 115327137A CN 202211237465 A CN202211237465 A CN 202211237465A CN 115327137 A CN115327137 A CN 115327137A
- Authority
- CN
- China
- Prior art keywords
- buffer solution
- human immunoglobulin
- reagent
- subtype
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 92
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 92
- 238000003018 immunoassay Methods 0.000 title claims abstract description 41
- 239000007853 buffer solution Substances 0.000 claims abstract description 102
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 63
- 210000002966 serum Anatomy 0.000 claims abstract description 58
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 38
- 239000003085 diluting agent Substances 0.000 claims abstract description 21
- 239000003550 marker Substances 0.000 claims abstract description 21
- 229960002685 biotin Drugs 0.000 claims abstract description 19
- 235000020958 biotin Nutrition 0.000 claims abstract description 19
- 239000011616 biotin Substances 0.000 claims abstract description 19
- 108010090804 Streptavidin Proteins 0.000 claims abstract description 15
- 239000006249 magnetic particle Substances 0.000 claims abstract description 15
- 239000011248 coating agent Substances 0.000 claims abstract 2
- 238000000576 coating method Methods 0.000 claims abstract 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 23
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 22
- 239000003755 preservative agent Substances 0.000 claims description 22
- 230000002335 preservative effect Effects 0.000 claims description 22
- 239000002981 blocking agent Substances 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 13
- 238000007789 sealing Methods 0.000 claims description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- 229940098773 bovine serum albumin Drugs 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 239000005018 casein Substances 0.000 claims description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 9
- 235000021240 caseins Nutrition 0.000 claims description 9
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 8
- 239000004098 Tetracycline Substances 0.000 claims description 8
- 229930027917 kanamycin Natural products 0.000 claims description 8
- 229960000318 kanamycin Drugs 0.000 claims description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 8
- 229930182823 kanamycin A Natural products 0.000 claims description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 8
- 229960002180 tetracycline Drugs 0.000 claims description 8
- 229930101283 tetracycline Natural products 0.000 claims description 8
- 235000019364 tetracycline Nutrition 0.000 claims description 8
- 150000003522 tetracyclines Chemical class 0.000 claims description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 239000012894 fetal calf serum Substances 0.000 claims description 7
- 239000007983 Tris buffer Substances 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
- 239000007995 HEPES buffer Substances 0.000 claims description 5
- 239000013504 Triton X-100 Substances 0.000 claims description 4
- 229920004890 Triton X-100 Polymers 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 claims description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical group C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000000565 sealant Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 239000000523 sample Substances 0.000 description 33
- 230000000052 comparative effect Effects 0.000 description 30
- 239000000872 buffer Substances 0.000 description 23
- 238000011156 evaluation Methods 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000010998 test method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- WQBPSJIAFZCNBR-UHFFFAOYSA-N 2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCO)C=C1 WQBPSJIAFZCNBR-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000021330 IgG4-related disease Diseases 0.000 description 1
- 208000037142 IgG4-related systemic disease Diseases 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
- G01N2470/04—Sandwich assay format
- G01N2470/06—Second binding partner specifically binding complex of analyte with first binding partner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211237465.XA CN115327137B (zh) | 2022-10-11 | 2022-10-11 | 一种人免疫球蛋白g4亚型化学发光免疫检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211237465.XA CN115327137B (zh) | 2022-10-11 | 2022-10-11 | 一种人免疫球蛋白g4亚型化学发光免疫检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115327137A true CN115327137A (zh) | 2022-11-11 |
CN115327137B CN115327137B (zh) | 2023-01-17 |
Family
ID=83914750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211237465.XA Active CN115327137B (zh) | 2022-10-11 | 2022-10-11 | 一种人免疫球蛋白g4亚型化学发光免疫检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115327137B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105954267A (zh) * | 2016-04-20 | 2016-09-21 | 北京中航赛维生物科技有限公司 | 一种抗组蛋白抗体IgG的磁微粒化学发光定量测定试剂盒及制备和检测方法 |
CN110068689A (zh) * | 2019-05-23 | 2019-07-30 | 贵州盛世康生物科技有限公司 | 一种免疫球蛋白IgG4测定试剂 |
CN110178034A (zh) * | 2017-01-18 | 2019-08-27 | 埃森仪器公司Dba埃森生物科学公司 | 用于从生物样品中测定免疫球蛋白γ(IgG)抗体同种型浓度的方法和试剂 |
CN111566214A (zh) * | 2017-07-06 | 2020-08-21 | 日东纺绩株式会社 | 抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂 |
CN111707835A (zh) * | 2020-07-01 | 2020-09-25 | 珠海丽珠试剂股份有限公司 | 用于检测IgG4的组合物、试剂盒、应用及检测方法 |
CN114264826A (zh) * | 2021-12-24 | 2022-04-01 | 青岛汉唐生物科技有限公司 | 人免疫球蛋白g4试剂盒 |
-
2022
- 2022-10-11 CN CN202211237465.XA patent/CN115327137B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105954267A (zh) * | 2016-04-20 | 2016-09-21 | 北京中航赛维生物科技有限公司 | 一种抗组蛋白抗体IgG的磁微粒化学发光定量测定试剂盒及制备和检测方法 |
CN110178034A (zh) * | 2017-01-18 | 2019-08-27 | 埃森仪器公司Dba埃森生物科学公司 | 用于从生物样品中测定免疫球蛋白γ(IgG)抗体同种型浓度的方法和试剂 |
CN111566214A (zh) * | 2017-07-06 | 2020-08-21 | 日东纺绩株式会社 | 抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂 |
CN110068689A (zh) * | 2019-05-23 | 2019-07-30 | 贵州盛世康生物科技有限公司 | 一种免疫球蛋白IgG4测定试剂 |
CN111707835A (zh) * | 2020-07-01 | 2020-09-25 | 珠海丽珠试剂股份有限公司 | 用于检测IgG4的组合物、试剂盒、应用及检测方法 |
CN114264826A (zh) * | 2021-12-24 | 2022-04-01 | 青岛汉唐生物科技有限公司 | 人免疫球蛋白g4试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN115327137B (zh) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103123319B (zh) | 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法 | |
CN109725160B (zh) | 一种降钙素原(pct)检测试剂盒 | |
CN112014577B (zh) | 一种提高gpc3检测灵敏度的试剂盒及其制备方法 | |
CN112526140A (zh) | 测定超敏肌钙蛋白t含量的磁微粒化学发光检测试剂盒 | |
EP2295969A1 (en) | Method for enhancing sensitivity or method for avoiding influence of hemoglobin in immunological measurement | |
WO2022100077A1 (zh) | 一种灵敏度高的抗Ro52抗体检测试剂盒 | |
CN110806487A (zh) | 一种用于人肝素结合蛋白检测的试剂盒及其制备方法 | |
CN114487433A (zh) | 一种游离IgE化学发光免疫检测试剂盒 | |
CN115327137B (zh) | 一种人免疫球蛋白g4亚型化学发光免疫检测试剂盒 | |
CN111007263B (zh) | 一种检测试剂盒及检测方法 | |
CN108362892B (zh) | 一种降钙素原胶体金免疫比浊法检测试剂 | |
WO2010013525A1 (ja) | 複合体の測定方法およびそれに用いるキット | |
CN114200129B (zh) | 组织金属蛋白酶抑制剂-2胶乳免疫比浊法血尿同检试剂盒 | |
CN111912990B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN115166229A (zh) | 一种测定神经丝轻链蛋白含量的直接化学发光法试剂盒及其制备方法 | |
US4107284A (en) | Radioimmunoassay procedure using a stabilized complex | |
CN114965986A (zh) | 用于检测血液中可溶性生长刺激表达基因2蛋白(st2)的试剂盒 | |
CN112198319A (zh) | 一种稳定性增强的人免疫球蛋白g4试剂盒 | |
JP5177677B2 (ja) | 抗原およびその抗原に対する抗体を測定する方法、並びにそれに用いる測定用試薬 | |
CN111929440A (zh) | 一种基于磁微粒化学发光免疫法检测dnase1l3的方法 | |
JPH07198721A (ja) | 免疫測定用緩衝液 | |
EP0908726B1 (en) | Method for measuring urinary trypsin inhibitor | |
JPH1151938A (ja) | 免疫学的ラテックス比濁定量用試薬 | |
US5242802A (en) | Processes for the stabilization of prostate specific antigen in natural matrices | |
CN111721937B (zh) | 人附睾蛋白4免疫比浊试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Room 205, Building B, No. 36 Huada Road, Houcheng Street, Zhangjiagang City, Suzhou City, Jiangsu Province, China (Zhangjiagang Free Trade Zone Science and Technology Entrepreneurship Park) Patentee after: Suzhou Diyalaibo Biotechnology Co.,Ltd. Country or region after: Zhong Guo Address before: Room 205, Building B, No. 36, Huada Road, Houcheng Street, Zhangjiagang City, Suzhou City, Jiangsu Province, 215634 Patentee before: Suzhou Huizhong Biotechnology Co.,Ltd. Country or region before: Zhong Guo |
|
CP03 | Change of name, title or address |